Novo picks AWS for pharma — can agents really speed up drug discovery

novo nordisk selected aws as its preferred cloud provider and strategic ai partner to integrate agentic ai into drug discovery processes like target identification and therapy design. the partnership establishes a co-innovation hub in london, aiming to automate and accelerate research workflows that historically take years. for the pharmaceutical industry, this move validates the belief that autonomous agents are the next frontier for operational efficiency. as other pharma companies likely follow suit, expect increased demand for specialized ai infrastructure capable of handling sensitive biological data.